SB-334867 - CAS 249889-64-3


SB-334867(cas 249889-64-3) is a selective non-peptide orexin OX1 receptor antagonist with a pKb value of 7.2. SB-334867 inhibited the orexin-A (10 nM) and orexin-B (100 nM)-induced calcium responses (pK(B)=7.27+/-0.04 and 7.23+/-0.03 respectively, n=8), but had no effect on the UTP (3 microM)-induced calcium response in CHO-OX(1) cells. SB-334867-A (10 microM) also inhibited OX(2) mediated calcium responses (32.7+/-1.9% versus orexin-A). Single-unit recordings in anesthetized rats demonstrated the central effects of the selective orexin-1 receptor antagonist SB-334867 (2 mg/kg, intravenous), as it reversed the excitatory effects of orexin-A administration (6 microg, intracerebroventricular) on the activity of locus coeruleus (LC) cells. The ICV injection of SB-334867 alone had no effect on the formalin-induced nociceptive behaviors. Pre-treatment with SB-334867 at a dose of 0.5 nmol significantly attenuated the analgesia induced by morphine (at dose 1.5mg/kg of morphine; interphase and phase 2B and at dose 3mg/kg of morphine just phase 2B of formalin test). Administered alone, SB-334867 (30 mg/kg, but not lower doses) significantly reduced food intake and most active behaviours (eating, grooming, sniffing, locomotion and rearing), while increasing resting. Pretreatment with SB-334867 dose-dependently blocked these effects of orexin-A, with significant antagonism evident at dose levels (3-10 mg/kg) below those required to produce intrinsic behavioural effects under present test conditions in rats.

Catalog Number: I002847

CAS Number: 249889-64-3

PubChem Substance ID:355039650

Molecular Formula: C17H14ClN5O2

Molecular Weight:355.78

Purity: ≥95%

* For research use only. Not for human or veterinary use.

Synonym

SynonymsSB-334867; SB 334867; SB334867;1-(2-methyl-1,3-benzoxazol-6-yl)-3-(1,5-naphthyridin-4-yl)urea

Property

Molecular Formula: C17H14ClN5O2
Molecular Weight355.78
Target:OX Receptor
Solubility10 mM in DMSO
Purity≥95%
StorageStore at -20°C
Overview of Clinical ResearchOriginator: GlaxoSmithKline<br /> Class: Benzoxazoles; Obesity therapies; Urea compounds<br /> Mechanism of Action: Orexin receptor antagonists<br /> Orphan Drug Status: No<br />
IC507.2 (pKb)